1. Pink Sheet
  2. >>Market Access

Keytruda, Opdivo May Be Only Part B Drugs Chosen For Medicare Negotiation In First Applicable Year

 
• By Cathy Kelly

In general, more Part D drugs will be eligible than Part B drugs in the early years of the program because Part D drugs have higher levels of spending and so will dominate the list of candidates. A new report sizes up the drugs that would qualify for Medicare Price negotiation in 2026-2028.

Boehringer Ingelheim May Face Price Negotiation For Six Drugs In 2026-2028. • Source: Shutterstock

Merck & Co., Inc.’s Keytruda and Bristol Myers Squibb Company’s Opdivo might be the only Medicare Part B drugs that will be subject to negotiated prices in 2028, the first year that Part B drugs will be eligible, according to an analysis by Sean Dickson, West Health Policy Center, and Immaculada Hernandez, University of California, San Diego.

Published in the Journal of Managed Care Pharmacy, the analysis forecasts the drugs and biologics whose prices will be negotiated...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Woodcock: Do Not Do The Wrong Study, Even If Against US FDA Advice

 
• By Sarah Karlin-Smith

The former CDER director said she tells sponsors not to conduct an FDA-recommended study design or randomized trial if it will not work.

AI Will Bolster, Not Squelch, Patient Voice In Clinical Research, US FDA Says

 
• By Sue Sutter

Artificial intelligence tools used for clinical research should be developed with input from patients and focus on their needs and abilities, FDA experts said.

UK Looks To Auto-Match NHS Patients With Clinical Trials To Boost Recruitment

 
• By Vibha Sharma

The UK government is making it easier for millions of people to participate in clinical trials and is boosting transparency around how studies are delivered across the National Health Service.